Standard BioTools exits SomaScan for $388M, cuts 20% of workforce, receives Nasdaq delisting notice

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  Received Nasdaq delisting notice April 20, 2026 for bid price below $1.00 for 30 consecutive days; must regain compliance by October 19, 2026 or face delisting, which would materially harm liquidity and capital-raising ability.

  Risk Factors: Nasdaq Delisting verify on EDGAR →
• high

  Sold SomaScan Business (aptamer-based proteomics) to Illumina for $388.2M net cash, recognizing $172.3M pre-tax gain; company now focuses solely on mass cytometry (CyTOF, Hyperion) and microfluidics (Biomark) platforms.

  MD&A: SomaScan Divestiture verify on EDGAR →
• high

  Reduced global workforce by ~20% through two restructuring actions: consolidated R&D from South San Francisco to Singapore, relocated headquarters to Boston, and aligned headcount with smaller continuing-operations revenue base.

  MD&A: Restructuring verify on EDGAR →